Based on this, immune checkpoint inhibitors targeting PD-1/PD-L1 signaling have made remarkable achievements in the clinical treatment of a variety of tumors, which has significantly improved the ability of tumor immunotherapy. This evidence concerns the gene CD274 and neoplasm.